GE HealthCare Technologies' Q1 Update Sets the Stage for the Next Leg of the Story

GE HealthCare Technologies (GEHC) has kicked off 2026 with Q1 results that sit on top of a solid recent run, with Q4 2025 revenue at US$5.7 billion and basic EPS of US$1.29, backed by net income of US$589 million. Over the past few quarters, the company has seen revenue move from US$5.3 billion in Q4 2024 to US$5.7 billion in Q4 2025, while basic EPS across 2025 ranged between roughly US$0.98 and US$1.29, giving you a clear view of how the earnings line is tracking. Margins look steady rather than explosive here, setting up this latest report as a check on how durable that profitability profile really is.

See our full analysis for GE HealthCare Technologies.

With the quarterly scorecard on the table, the next step is to see how these numbers line up with the big narratives around GE HealthCare, which is where expectations about growth, risks, and long term earnings power either get backed up or pushed into question.

TTM earnings of US$2.1b on a 10.1% margin

• Over the trailing twelve months to Q1 2026, GE HealthCare reports about US$2.1b of net income on US$20.6b of revenue, which lines up with the 10.1% net margin cited in the analysis data.
• Analysts' consensus view links this steady 10.1% margin to potential future expansion, expecting it to reach 11.4%. However, the flat margin in the latest data keeps the burden of proof on execution.
  • The consensus narrative highlights new products such as Total Body PET and Photon Counting CT, along with more recurring digital revenue, as possible future margin drivers, while current trailing margins remain at 10.1% with no improvement in the reported data.
  • Forecast earnings growth of about 8.9% per year is described as achievable by 2029, but with trailing five year earnings growth at 1.9% per year, investors need to judge whether that shift is realistic or too optimistic.

P/E of 13x versus richer industry multiples

• At a share price of US$59.49 and a trailing P/E of about 13x compared with 24x for the US medical equipment industry average and 32.3x for peers, GE HealthCare trades on meaningfully lower earnings multiples than its reference group.
• Supporters of the bullish view see this gap as an opportunity, but the numbers also illustrate why the market might be cautious.
  • The DCF fair value in the dataset is US$110.28, and the allowed analyst price target is US$85.37, both above the current US$59.49 share price. This supports the bullish case that the current multiple may not fully reflect forecast earnings.
  • At the same time, trailing revenue is growing at about 4% per year and net margin is flat at 10.1%, so anyone leaning into the bullish view that the stock could move closer to those valuation markers needs to be comfortable with relatively modest growth assumptions.

Bulls argue that the current 13x P/E and wide gap to both DCF fair value and target price leave room if earnings land as expected, and you can see their full reasoning in the 🐂 GE HealthCare Technologies Bull Case.

Debt coverage risk sits beside growth ambitions

• The analysis flags a major risk in that reported debt is not well covered by operating cash flow over the last 12 months, even as the business produced about US$2.1b of net income and carries a 10.1% net margin.
• Bears focus on this cash coverage issue and on external pressures such as tariffs and China regulation, and the data give that argument some weight.
  • The bearish narrative notes that tariffs are estimated to hit adjusted EPS by US$0.85 and that free cash flow has been reduced by tariff impacts and inventory build, which aligns with the concern that operating cash flow is not comfortably covering debt.
  • With analysts still expecting revenue to grow around 4.8% annually and earnings to reach about US$2.7b by 2029, skeptics question whether those targets are compatible with weaker cash coverage and potential headwinds from trade and regulatory changes.

Skeptics argue that weak cash coverage of debt and tariff pressure could limit how much these earnings forecasts are worth paying up for, which is the angle unpacked in the 🐻 GE HealthCare Technologies Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for GE HealthCare Technologies on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both risks and rewards on the table, the real question is how it all stacks up for you right now. Move quickly, review the details, and weigh the balance of 5 key rewards and 1 important warning sign

See What Else Is Out There

GE HealthCare pairs modest trailing revenue growth and flat 10.1% margins with debt that is not well covered by operating cash flow, leaving its balance sheet strength in question.

If you want ideas where financial footing looks firmer, check out the solid balance sheet and fundamentals stocks screener (45 results) today and compare companies with healthier cash coverage and balance sheets.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.